Semaglutide and heart health have a real connection, but it applies to specific groups. In SELECT, adults who already had cardiovascular disease and overweight or obesity—but no diabetes—had fewer heart attacks, strokes, or cardiovascular deaths with branded Wegovy than with placebo. The absolute difference was 8.0% versus 6.5% over about 40 months. A separate heart-failure trial found better symptoms and walking ability. Neither result means semaglutide treats every heart condition, and neither establishes the same outcomes for compounded semaglutide.

Semaglutide and heart health in real numbers

Semaglutide is a GLP-1 medicine, meaning it copies a gut-hormone signal involved in appetite and blood sugar. Its strongest direct heart evidence for people without diabetes comes from SELECT, a 2023 trial of 17,604 adults. Everyone was at least 45, had a body mass index of 27 or higher, and already had cardiovascular disease from a prior heart attack, stroke, or artery disease in the legs.

Researchers assigned people by chance to weekly 2.4 mg branded Wegovy or placebo, a look-alike treatment without semaglutide. Both groups continued ordinary care for blood pressure, cholesterol, and other heart risks. Over an average of 39.8 months, a major event—cardiovascular death, a nonfatal heart attack, or a nonfatal stroke—occurred in 569 of 8,803 people taking semaglutide and 701 of 8,801 taking placebo. That is 6.5% versus 8.0% (SELECT, New England Journal of Medicine, 2023).

The often-quoted 20% is the relative reduction, taken from the trial's hazard ratio of 0.80, which compares the two groups' event rates over time. The absolute reduction—the difference a person can picture—was 1.5 percentage points, or about 15 fewer people with an event for every 1,000 treated during the trial. Side effects mattered too: about 1 in 6 people assigned semaglutide, 16.6%, stopped it because of an adverse event, compared with 8.2% on placebo.

What the Wegovy heart indication actually covers

In March 2024, the FDA added a cardiovascular indication to Wegovy injection. An indication is the specific use described on a medicine's label. It covers reducing the risk of cardiovascular death, heart attack, and stroke in adults with established cardiovascular disease and either obesity or overweight (FDA label, 2024).

That wording matters. SELECT was secondary prevention, meaning the participants already had disease and were trying to avoid another serious event. It did not test whether semaglutide prevents a first heart attack in an otherwise low-risk person, and it was not a substitute for standard heart care.

For how the medicine is used for weight management, the semaglutide weight-loss guide covers the separate evidence and expectations.

Heart failure is a different question

Heart failure does not always mean a weak squeeze. HFpEF, or heart failure with preserved ejection fraction, means the heart can squeeze out a normal share of blood but is often too stiff to fill easily. People may feel breathless, tired, or limited in everyday movement.

STEP-HFpEF studied 529 adults with this condition and obesity for 52 weeks. On a 100-point score of symptoms and daily function, the average improvement was 16.6 points with semaglutide and 8.7 with placebo. In a six-minute walking test, the semaglutide group added an average of 21.5 meters, compared with 1.2 meters in the placebo group (STEP-HFpEF, New England Journal of Medicine, 2023).

Those are encouraging quality-of-life and movement results. The trial was not designed to show that semaglutide prevents death from heart failure. It also enrolled people with obesity and this particular kind of symptomatic heart failure, not everyone who has shortness of breath or a heart diagnosis.

What changed in 2026

As of September 6, 2026, the day this article was written, two fresh developments add useful context. A SELECT analysis published August 18 found that hsCRP—a blood marker of inflammation—fell 37.8% by week 104 with semaglutide. The drop appeared as early as weeks 4 and 8 and was also seen in people who had not lost weight; the authors' modeling suggests lower inflammation may explain part, but not all, of the heart result (Circulation, 2026).

Then, on August 28, the 2026 European Society of Cardiology heart-failure guideline gave semaglutide or tirzepatide a Class IIa recommendation for people with HFpEF and obesity. Class IIa means clinicians should consider the treatment for the right patient; it is not an automatic choice for everyone. The ESC's August 29 explanation confirms both medicines and that specific patient group.

This update moves the heart-failure evidence into European clinical guidance. It does not turn either medicine into a replacement for established heart-failure treatment or a reason to start one without a cardiology review.

What these studies do not prove

The trial results belong to the products and populations actually studied. Someone without established cardiovascular disease cannot assume the SELECT numbers describe their risk. Someone with a different type of heart failure cannot assume the STEP-HFpEF findings transfer to them. The newer inflammation analysis offers a possible explanation, not proof of one single mechanism.

Compounded semaglutide was not tested in SELECT or STEP-HFpEF. Through Promise, semaglutide is dispensed as a compounded medication, which is different from an FDA-approved product: the formulation offered here is not FDA-approved. Compounding means a pharmacy prepares a medication for an individual prescription; it does not make that preparation the branded product used in these trials. A licensed provider may still prescribe a compounded formulation; that decision is between the patient and the doctor.

The compounded semaglutide explainer goes deeper on that distinction, while semaglutide safety covers the screening questions and known risks.

The question to bring to a clinician

A useful conversation starts with the reason for asking. Prior heart attack or stroke, established artery disease, HFpEF, blood pressure medicines, kidney function, and current symptoms all change how this evidence fits. Tirzepatide now appears beside semaglutide in the European heart-failure guidance, but the two medicines are not interchangeable; the tirzepatide and semaglutide comparison explains their broader differences.

At Promise, a licensed provider reviews every request, and not everyone qualifies. Heart disease or heart-failure symptoms also deserve ongoing care from the clinician managing that condition, not a medication decision made in isolation.